Seasoned biopharma executive brings corporate development expertise to Sernova LONDON, ONTARIO--(Marketwired - May 7, 2014) - Sernova Corp. (TSX VENTURE:SVA) is pleased to announce that Mr. Nick Borrelly is joining Sernova in a consultant corporate development role. Mr. Borrelly has over 25 years' experience in corporate/business development as well as marketing and sales in the pharmaceutical (Ciba-Geigy, Novartis and Sanofi-Aventis) and biopharma industries. As President of Camargue Consulting, he specializes in development, evaluation and in-licensing of technologies, initiation of strategic alliances with multi-national corporate partners, and leading sales and marketing teams for commercial stage products.
"Nick's extensive corporate development network and partnering expertise will be invaluable to creating significant shareholder value through attracting strong commercialization partners for our products. As Sernova is now exploring additional clinical applications of the Cell Pouch™, establishing corporate partners to help accelerate development has become an important part of our corporate strategy forward", stated Dr. Philip Toleikis, Sernova's President and CEO.
Mr. Borrelly said, "I am excited to work with Sernova's CEO, Dr. Philip Toleikis, and his team to fully implement the strategic vision for its disruptive technologies for the cell-based treatment of chronic diseases."
Nick's past roles include Manager, Business Development - Licensing & Acquisitions with Sanofi Aventis Pharma Canada; Vice President, Business Development for MNLpharma (U.K.) Ltd.; and Vice President, Business Development for CV Technologies/Afexa Life Sciences Inc. As a Director with Nucleus BioScience Inc., he coordinated its amalgamation with Stratos BioSciences Inc. and Brightwave Technologies Inc. to create SNB Capital Corp., which subsequently took the biotherapeutics company Protox Therapeutics Inc. (now Sophiris Bio Inc) public in 2004. Nick is currently a member of the Board of Directors of Eternity Healthcare, and Auxellence Health Corporation.
Click here to view the full news release online.